Your session is about to expire
← Back to Search
Behavioural Intervention
Mindfulness Apps for Lung Cancer (CALM IT Trial)
N/A
Waitlist Available
Led By Daniela Molena, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to test if an app (AmDTx) can improve care for lung cancer patients before and after surgery.
Who is the study for?
This trial is for adults over 18 with lung cancer, scheduled for surgery, who own a smartphone/tablet and can use it. They should understand the study, consent to participate, be willing to practice mindfulness, and have a high distress level. People already using meditation apps or needing pre-surgery chemo/radiation cannot join.
What is being tested?
The study tests if the AmDTx app helps reduce anxiety in lung cancer patients before and after surgery. The app adapts to patient needs via doctor's prescriptions. Participants will either use this mindfulness program or a control intervention (CI) alongside answering questionnaires.
What are the potential side effects?
Since this trial involves non-medical interventions like mindfulness apps and questionnaires rather than drugs or invasive procedures, significant side effects are not expected.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adherence Retention rate
Secondary study objectives
Decrease in anxiety symptoms
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: MBCR (mindfulness-based cancer survivorship group) (AmDTx-PCSP)Experimental Treatment2 Interventions
Patients randomized to the MBCR group will receive remote AmDTx-PCSP in the perioperative period (initiated at least 2 weeks before surgery). AmDTx-PCSP will be continued after surgery, for a minimum of 6 weeks total. AmDTx-PCSP is a step-by-step program including meditation training and other activities relevant for people living with cancer. The participants are asked to use AmDTx for about 20-30 minutes per day, at least 4 days per week, for 6 weeks. The participants are free to proceed at a faster pace and use AmDTx more than 20-30 per day if they choose. The first 3 modules of the program are required, and then the participant will be able to pick 3 additional modules based on topics that are most meaningful to them.
Group II: CI (control) group (AmDTx-2048)Active Control2 Interventions
Patients randomized to the CI group will use a game called "2048", a cognitive training app, which is used as an control condition to control for expectancy and daily engagement. The participants will use AmDTx-2048 to engage in cognitive training with a puzzle game. The participants are asked to use AmDTx for about 20-30 minutes per day, at least 4 days per week, for 6 weeks. The participants are free to proceed at a faster pace and use AmDTx more than 20-30 per day if you choose. In this puzzle game, the participants will slide numbered tiles around a grid, matching tiles of the same value to combine them into one new tile displaying the sum of the previous two numbers. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit.
Find a Location
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,965 Previous Clinical Trials
596,977 Total Patients Enrolled
Daniela Molena, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
4,110 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger